EUVIMEDEUVIMED entdecken
Vergleichsstudie

Lower Risk of Type 2 Diabetes Mellitus With PCSK9 Inhibitors Compared With Other Lipid‐Lowering Agents Among Patients With Hyperlipidaemia

Jiun-Lu Lin, Christine Hsu, Shao-Wei Lo, Nishtha Nigam, Mahima Shenoi, Yung-Fang Tu, Hardikkumar Bhanderi, Chien-Chin Chen iD, Yu-Jung Su, Hui-Chin Chang iD, Shuo-Yan Gau iD

Diabetes/Metabolism Research and Reviews · 2026-07 · 42 (5)

DOI: 10.1002/dmrr.70188 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 11.06.2026. Verfasst von Jiun-Lu Lin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, PCSK9 Inhibitors, Hyperlipidemias, Hypolipidemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The purpose of this paper is to compare the risk of incident type 2 diabetes mellitus (T2DM) among patients with hyperlipidaemia treated with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors versus statins and other nonstatin lipid‐lowering agents. Methods and Results This target trial emulation study used a retrospective, propensity score–matched cohort design based on the TriNetX Global Collaborative Network. Adults (≥ 18 years) with hyperlipidaemia diagnosed between January 2015 and December 2024 were included. Patients with preexisting diabetes, malignancy, or death during follow‐up were excluded. Three active‐comparator analyses compared PCSK9 inhibitors with statins, ezetimibe and fenofibrates under a per‐protocol framework. Propensity score matching (1:1) balanced demographics, comorbidities, BMI, lipid profiles and healthcare utilization. Incident T2DM was identified using ICD‐10 codes and analysed. Multiple sensitivity analyses including intention‐to‐treat analysis were performed. In the main analysis model, PCSK9 inhibitor use was associated with a significantly lower risk of incident T2DM than statins (HR 0.815; 95% CI 0.764–0.869), ezetimibe (HR 0.919, 95% CI 0.867–0.974), and fenofibrates (HR 0.517; 95% CI 0.493–0.542). Findings were consistent across subgroups and sensitivity analyses. No significant difference was observed between different PCSK9 inhibitor modalities.

Conclusions

In this large‐scale real‐world cohort, PCSK9 inhibitors were associated with a lower risk of new‐onset T2DM compared with other lipid‐lowering therapies, supporting their metabolic safety and clinical use in patients at risk for diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2PCSK9 InhibitorsHyperlipidemiasHypolipidemic AgentsAnticholesteremic AgentsHumansFemaleMiddle AgedMaleRetrospective StudiesAgedProprotein Convertase 9Follow-Up StudiesPrognosisRisk FactorsIncidenceHydroxymethylglutaryl-CoA Reductase Inhibitors

Stichwörter der Autor:innen

PCSK9 inhibitorshyperlipidaemialipid lowering agentsreal‐world studytype 2 diabetes mellitus

Substanzen

PCSK9 InhibitorsPCSK9 protein, humanHypolipidemic AgentsProprotein Convertase 9Anticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
  • Department of Medicine, MacKay Medical University, New Taipei City, Taiwan.
  • Department of Medicine, Monmouth Medical Center, Robert Wood Johnson/Barnabas Health Care System, Long Branch, New Jersey, USA.
  • Department of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Department of Internal Medicine, Rochester General Hospital, Rochester, New York, USA.
  • Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

ORCID-Profile: Chien-Chin Chen, Hui-Chin Chang, Shuo-Yan Gau

Zitieren

APA

Lin, J. L., Hsu, C., Lo, S. W., Nigam, N., Shenoi, M., Tu, Y. F., Bhanderi, H., Chen, C. C., Su, Y. J., Chang, H. C., & Gau, S. Y. (2026). Lower Risk of Type 2 Diabetes Mellitus With PCSK9 Inhibitors Compared With Other Lipid‐Lowering Agents Among Patients With Hyperlipidaemia. Diabetes/Metabolism Research and Reviews, 42(5). https://doi.org/10.1002/dmrr.70188

Vancouver

Lin JL, Hsu C, Lo SW, Nigam N, Shenoi M, Tu YF, et al. Lower Risk of Type 2 Diabetes Mellitus With PCSK9 Inhibitors Compared With Other Lipid‐Lowering Agents Among Patients With Hyperlipidaemia. Diabetes/Metabolism Research and Reviews. 2026;42(5). doi:10.1002/dmrr.70188

BibTeX
@article{Lin2026,
  author = {Lin, Jiun-Lu and Hsu, Christine and Lo, Shao-Wei and Nigam, Nishtha and Shenoi, Mahima and Tu, Yung-Fang and Bhanderi, Hardikkumar and Chen, Chien-Chin and Su, Yu-Jung and Chang, Hui-Chin and Gau, Shuo-Yan},
  title = {Lower Risk of Type 2 Diabetes Mellitus With PCSK9 Inhibitors Compared With Other Lipid‐Lowering Agents Among Patients With Hyperlipidaemia},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2026},
  volume = {42},
  number = {5},
  doi = {10.1002/dmrr.70188}
}
Kostenlos starten →